Efficacy of Osimertinib in Patients With Lung Cancer

Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLC

NCT06376084 ·Status: ACTIVE_NOT_RECRUITING

Osimertinib for Advanced EGFR-positive NSCLC Patients

NCT05037331 ·Status: RECRUITING

The Recurrence Gene Profiles of Adjuvant Osimertinib Therapy in Resected Non-Small-Cell Lung Cancer

NCT06477055 ·Status: RECRUITING

A Study of Osimertinib-based Adaptive Treatment Guided by ctDNA EGFRm+ Monitoring in NSCLC

NCT07058519 ·Status: RECRUITING ·Phase: PHASE2

A Study Osimertinib in Patients With Stage 4 Non-small Cell Lung Cancer With Uncommon EGFR Mutations

NCT03434418 ·Status: COMPLETED ·Phase: PHASE2

Efficacy and Safety of Osimertinib for HK Chinese With Metastatic T790M Mutated NSCLC-real World Setting.

NCT03219970 ·Status: COMPLETED

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

NCT03191149 ·Status: RECRUITING ·Phase: PHASE2

Effect of Osimertinib in Ethnic Chinese With EGFR and T790M Mutated NSCLC

NCT03133234 ·Status: COMPLETED

A Multi-Centre, Prospective, Non-Interventional Study to Intensively Monitor the Safety of Osimertinib in Clinical Practice Among Chinese NSCLC Patients

NCT03485326 ·Status: COMPLETED

Safety and Efficacy of Combination Osimertinib and Ipilimumab in Patients w EGFR Mutated NSCLC

NCT04141644 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

Study of Osimertinib in Patients with a Lung Cancer with Brain or Leptomeningeal Metastases with EGFR Mutation

NCT04233021 ·Status: COMPLETED ·Phase: PHASE2

Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutation

NCT03414814 ·Status: COMPLETED ·Phase: PHASE2

Osimertinib With Bevacizumab for Leptomeningeal Metastasis From EGFR-mutation Non-Small Cell Lung Cancer

NCT04425681 ·Status: UNKNOWN ·Phase: PHASE2

Primary Tumor Resection Plus Osimertinib in Advanced EGFR-mutant Non-small Cell Lung Cancer

NCT07177092 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Osimertinib Plus Chemotherapy in Uncommon EGFRm NSCLC

NCT05215951 ·Status: TERMINATED ·Phase: PHASE2

Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation

NCT04322890 ·Status: RECRUITING ·Phase: PHASE2

High-dose Furmonertinib Versus Osimertinib in Advanced EGFRm NSCLC Patients With Brain Metastases

NCT06319950 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Efficacy and Safety of 80mg Osimertinib in Patients With Non-small Cell Lung Cancer(NSCLC)

NCT04563871 ·Status: COMPLETED ·Phase: PHASE2

A Phase 2 Study of Osimertinib and S-1 in Treatment Resistant EGFR Mutant NSCLC

NCT05773092 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

JMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Common Mutations

NCT06391944 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Erlotinib Versus Gemcitabine/Carboplatin in Chemo-naive Stage IIIB/IV Non-Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Exon 19 or 21 Mutation

NCT00874419 ·Status: COMPLETED ·Phase: PHASE3

Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC

NCT05009836 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations

NCT06194448 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

A Study With Central Nervous System Metastatic EGFR Mutation Positive Non-small Cell Lung Cancer

NCT05991193 ·Status: RECRUITING

Osimertinib With or Without Savolitinib as 1L in de Novo MET+, EGFR+ NSCLC

NCT05163249 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2